Advantage Novo As Victoza Gets CV Benefit Okay in Europe

 
• By Kevin Grogan

Victoza is the only drug in the GLP-1 class in Europe to have a label that includes the prevention of CV events (and only the second antidiabetic after Boehringer Ingelheim/Lilly’s SGLT2 inhibitor Jardiance) which will help slow down market share loss to Lilly's Trulicity.

First
Staying on top: Victoza boosted by CV benefit label update • Source: Shutterstock

More from New Products

More from Scrip